Emvision Medical Devices Ltd (EMV) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Emvision Medical Devices Ltd stock A$0.16, price A$1.46, that is 89.0% below the price, quality 29 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.
How to read this chart
60‑month range A$1.13 – A$3.30 · fair‑value band A$0.1000 – A$0.1900 · the A$1.46 price screens above the A$0.1600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.
Follow Emvision Medical Devices in your weekly email
Every Wednesday you see whether Emvision Medical Devices is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia.
Show moreShow less
It offers non-invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients.
The company was incorporated in 2017 and is based in Macquarie Park, Australia.
Stock analysis
Emvision Medical Devices Ltd (EMV) currently trades at A$1.46, while our model-based Fair Value estimate is A$0.1600, 89.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: A$0.1000 (bear) to A$0.1900 (bull), the price of A$1.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Emvision Medical Devices Ltd reported revenue of A$5.1M in FY2025 versus A$1.7M in FY2021, a compound +31.3%/yr. Reported net income was −A$8.3M in FY2026.
Key figures
Market cap A$136M (≈ $94.7M) Micro · P/S ratio 16.8 · EPS (TTM) A$−0.0900 · Net margin −99.5% · Return on equity −66.4% · Return on assets (EBIT) −70.1% · Operating margin −101% · Revenue (TTM) A$8.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −89%, EMV screens richer than that median.
Fair Value models
BearA$0.1000Fair Value A$0.1600BullA$0.1900
Price A$1.46 · Downside -89.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−55.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.8%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.4%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−354.3% (2020) → −160.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Emvision Medical Devices Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 323 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−89.0% · Bottom 25%
Profitability
Return on assets−36.1% · Bottom 25%
Net margin (12 months)−99.5% · Bottom 25%
Operating margin (12 months)−100.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)187.5% · Top 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B8.61× · Priciest 25%
P/S (12 months)16.24× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)100· sector 36
PAST (return on equity)0· sector 16
HEALTH (low debt)91· sector 98
DIVIDEND (yield)0· sector 36
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Emvision Medical Devices Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EMV
Frequently asked questions
Is Emvision Medical Devices Ltd (EMV) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of A$0.1600 versus a price of A$1.46, about 89% lower (overvalued).
What is the fair value of EMV?
Our model-based fair value for Emvision Medical Devices Ltd is A$0.1600 (as of Oct 30, 2026), built from audited fundamentals. The current price: A$1.46.
What is the quality score of EMV?
Emvision Medical Devices Ltd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Emvision Medical Devices Ltd (EMV)?
Our model-based price target is the fair value of A$0.1600 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario A$0.1000, optimistic scenario A$0.1900. It is a calculation from audited fundamentals, not an analyst target.
What is the Emvision Medical Devices Ltd stock forecast for 2026?
Our models put fair value at A$0.1600, about 89% lower versus a price of A$1.46 (overvalued). Cautious scenario A$0.1000, optimistic scenario A$0.1900. The calculation is refreshed regularly with new filings.
What is the revenue of Emvision Medical Devices Ltd (EMV)?
Emvision Medical Devices Ltd reported trailing-twelve-month revenue of about A$8.4M (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Emvision Medical Devices Ltd (EMV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emvision Medical Devices Ltd it is A$0.1600 per share (as of Oct 30, 2026), against a price of A$1.46. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Emvision Medical Devices Ltd stock overvalued or undervalued in 2026?
As of Oct 30, 2026, EMV trades above its calculated fair value: price A$1.46, fair value A$0.1600, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EMV?
No. The price is what the market pays today (A$1.46); the fair value is what the company's own numbers justify (A$0.1600). For Emvision Medical Devices Ltd the two are A$1.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Emvision Medical Devices Ltd worth?
The market values Emvision Medical Devices Ltd at about A$136M (market capitalisation, as of Oct 30, 2026). Per share that is A$1.46; our models calculate a fair value of A$0.1600 per share.
What do the bullish and bearish scenarios say about EMV?
Our models span a range for Emvision Medical Devices Ltd: cautious scenario A$0.1000, base A$0.1600, optimistic A$0.1900 per share (as of Oct 30, 2026, price A$1.46). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Emvision Medical Devices Ltd (EMV)?
Balance-sheet figures for Emvision Medical Devices Ltd (as of Oct 30, 2026): return on equity −66.4%, debt of 0.17 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is EMV from its 52-week high?
Emvision Medical Devices Ltd trades at A$1.46, about 25% below its 52-week high of A$1.96 and 2% above the low of A$1.43 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.1600 is for.
Which stocks are comparable to Emvision Medical Devices Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Emvision Medical Devices Ltd stock attractive at the current price?
The data as of Oct 30, 2026: price A$1.46, calculated fair value A$0.1600 (−89%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EMV calculated?
We run Emvision Medical Devices Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.1600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Emvision Medical Devices Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Emvision Medical Devices Ltd (EMV)?
The closing price on Nov 4, 2026 was A$1.46. Our model-based fair value is A$0.1600, about 89% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Emvision Medical Devices Ltd right now?
The price sits above even our optimistic bull case (A$0.1900). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (A$0.1000 to A$0.1900) leaves room in how you read the outcome.
Key figures of Emvision Medical Devices Ltd
How large is the market capitalisation of Emvision Medical Devices Ltd (EMV)?
The market capitalisation of Emvision Medical Devices Ltd is A$136M (≈ $94.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Emvision Medical Devices Ltd (EMV)?
The price-to-sales ratio of Emvision Medical Devices Ltd is 16.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Emvision Medical Devices Ltd (EMV)?
Earnings per share at Emvision Medical Devices Ltd are A$−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Emvision Medical Devices Ltd (EMV)?
The net margin of Emvision Medical Devices Ltd is −99.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Emvision Medical Devices Ltd (EMV)?
The return on equity (ROE) of Emvision Medical Devices Ltd is −66.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Emvision Medical Devices Ltd (EMV)?
On an EBIT basis the return on assets of Emvision Medical Devices Ltd is −70.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Emvision Medical Devices Ltd (EMV)?
The operating margin of Emvision Medical Devices Ltd is −101% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Emvision Medical Devices Ltd (EMV)?
Revenue at Emvision Medical Devices Ltd is growing +188% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Emvision Medical Devices Ltd (EMV) generate?
The free cash flow of Emvision Medical Devices Ltd is −A$6.4M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Emvision Medical Devices Ltd (EMV) hold?
Emvision Medical Devices Ltd holds more cash than debt, A$13.7M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Emvision Medical Devices Ltd in the live analysis
One click puts Emvision Medical Devices Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Oct 30, 2026